Patent No. US10995376 (titled "Systems and methods to detect rare mutations and copy number variation") on Jan 11, 2021. The application was issued on May 4, 2021.
’376 is related to the field of genetic analysis and molecular diagnostics, specifically focusing on the detection of rare mutations and copy number variations within cell-free polynucleotides. The technology addresses the inherent challenges of identifying low-frequency genetic signals, such as those derived from tumors or fetuses, which are often obscured by the high background noise and distortion typical of standard next-generation sequencing workflows.
The underlying idea behind ’376 is to utilize a digital sequencing approach that employs molecular tagging to distinguish true genetic variants from artifacts introduced during laboratory processing. By assigning identifiers to individual parent molecules before amplification, the system can collapse multiple sequencing reads into high-fidelity consensus sequences, effectively filtering out errors and providing a more accurate quantitative measure of the original genetic material.
The claims of ’376 focus on a method for preparing DNA libraries for sequencing by attaching a specific number of molecular barcodes to a population of DNA molecules. The number of unique barcodes, denoted as n, is strategically calibrated to be at least 2 but no more than 100,000 times the mean number of expected duplicate molecules that share identical start and stop positions, ensuring that cognate fragments can be uniquely identified even in samples containing up to 300,000 haploid human genome equivalents.
In practice, the invention works by ligating these molecular barcodes to cell-free DNA fragments, followed by amplification and selective enrichment of specific genomic regions of interest, such as actionable oncogenes. This targeted approach allows for the deep sequencing of progeny polynucleotides, which are then grouped into families based on their barcodes and genomic coordinates to reconstruct the sequence of the original parent molecule with high sensitivity.
This methodology differs from prior approaches by optimizing the conversion efficiency of the library preparation and using a mathematically defined diversity of tags to handle the natural overlap of fragmented DNA. By focusing on the relationship between the number of tags and the expected number of duplicate molecules, the system achieves a sensitivity threshold as low as 0.1%, enabling the detection of rare variants that would otherwise be lost in the baseline noise of conventional analog sequencing.
In the early 2010s when ’376 was filed, the analysis of genetic material from bodily fluids was typically implemented using standard sequencing protocols where the detection of rare variants was limited by the inherent error rates of the sequencing hardware. At a time when systems commonly relied on raw read depth to quantify genetic alterations, distinguishing low-frequency somatic mutations from background noise was non-trivial due to the accumulation of stochastic errors during library preparation and amplification. Furthermore, computational architectures for processing cell-free DNA often utilized uniform mapping and counting methods that did not account for the specific molecular diversity or the unique fragmentation patterns of extracellular polynucleotides.
The disclosed invention represents a meaningful technical advancement through the integration of molecular tagging and computational collapsing to generate high-fidelity consensus sequences from cell-free DNA. This architectural shift moves beyond simple read counting by utilizing unique identifiers and sequence start/stop positions to group progeny reads into families, thereby enabling the identification of the original parent polynucleotides. This capability enables the detection of rare mutations and copy number variations with a sensitivity exceeding the per-base error rate of the sequencing platform. By normalizing these consensus-derived measures against reference controls and applying probabilistic modeling, the system overcomes the technical constraint of distinguishing true biological variants from artifacts introduced during amplification and sequencing.
The patent contains a total of 20 claims, with claims 1 and 20 serving as the independent claims. These independent claims focus on a method for preparing DNA molecules for sequencing by attaching a specific range of molecular barcodes based on expected duplicate molecule counts, followed by amplification and selective enrichment of target regions. The dependent claims serve to further define the process by specifying the biological sources of the DNA, the physical properties and quantities of the genetic material, the specific configurations and lengths of the molecular barcodes, and the technical parameters for the amplification and enrichment stages.
Definitions of key terms used in the patent claims.
US Latest litigation cases involving this patent.

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Get instant alerts for new documents